LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Начало・Списък с акции・Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

285.29 -0.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

284.14

Максимум

291.38

Ключови измерители
By Trading Economics
Приходи	20M 206M
Продажби	70M 1.2B
P/E Средно за сектора	71.389 51.415
EPS	1.99
Марж на печалбата	17.649
Служители	2,500
EBITDA	7.1M 152M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+57.76% upside

Дивиденти
By Dow Jones
Следващи печалби	30.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.1B 38B
Предишно отваряне	285.89
Предишно затваряне	285.29

Настроения в новините

By Acuity

50%

157 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

256.565 / 269.81 Подкрепа & съпротива

Alnylam Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.05.2026 г., 23:10 ч. UTC

Горещи акции

Stocks to Watch: Agilysys, XP

18.05.2026 г., 18:44 ч. UTC

Значими двигатели на пазара

Claritev Shares Recover After Comments About DOJ

18.05.2026 г., 23:55 ч. UTC

Печалби

Review & Preview: Earnings' Last Gasp -- Barrons.com

18.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

18.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18.05.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18.05.2026 г., 22:31 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18.05.2026 г., 22:30 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18.05.2026 г., 22:25 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18.05.2026 г., 22:24 ч. UTC

Придобивния, сливания и поглъщания

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

18.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

18.05.2026 г., 20:25 ч. UTC

Печалби

Correct: XP 1Q Total Client Assets BRL1.53T

18.05.2026 г., 20:23 ч. UTC

Печалби

XP 1Q Total Client Assets BRL1.53B

18.05.2026 г., 20:19 ч. UTC

Печалби

XP 1Q Adj EPS BRL2.49 >XP

18.05.2026 г., 20:19 ч. UTC

Печалби

XP 1Q Rev BRL4.73B >XP

18.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18.05.2026 г., 19:00 ч. UTC

Печалби

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18.05.2026 г., 18:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18.05.2026 г., 18:17 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18.05.2026 г., 17:22 ч. UTC

Пазарно говорене

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18.05.2026 г., 16:57 ч. UTC

Придобивния, сливания и поглъщания

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18.05.2026 г., 16:57 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

18.05.2026 г., 16:57 ч. UTC

Пазарно говорене

Commodities Higher as Traders Want Physical Assets -- Market Talk

18.05.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Vinci Doesn't Set Out Financial Details of Deal

18.05.2026 г., 16:50 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18.05.2026 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18.05.2026 г., 16:49 ч. UTC

Придобивния, сливания и поглъщания

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18.05.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Vinci Buys Canada's Modern Group of Companies

Сравнение с други в отрасъла

Ценова промяна

Alnylam Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

57.76% нагоре

12-месечна прогноза

Среден 452.73 USD 57.76%

Висок 550 USD

Нисък 330 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Alnylam Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

Купи

Задържане

Продай

Според 18 анализатори, дали борсови рейтинги на Alnylam Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

256.565 / 269.81Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

157 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.